ArticleAmerican journal of translational research2023
Protective effect of ulinastatin on myocardial injuries in children with severe pneumonia.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the effect of ulinastatin on myocardial protection in children with severe pneumonia.
methodsIn this retrospective study, children with severe pneumonia were divided into two groups based on their treatment methods. The control group (n=39) received anti-infection therapy, while the experimental group (n=43) received anti-infection therapy combined with ulinastatin. The clinical treatment efficacy, levels of peripheral inflammatory factors, T lymphocyte subsets, QT dispersion and adverse reactions of the two groups were observed and compared before and after treatment.
resultsThe clinical efficacy was improved after intervention (P<0.05), and the total response rate was 88.4% (38/43) in the experimental group and 64.1% in the control group. The post-treatment levels of interleukin-8 (IL-8), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) in the peripheral blood were lower than those before treatment, with significant differences (P<0.05). After treatment, the serum levels of CD3+, CD4+ and CD4+/CD8+ in the experimental group were significantly higher than those in the control group, whereas the levels of IL-6, IL-8 and hscRP in the peripheral blood were lower in the experimental group than those in the control group, with significant differences (P<0.05). The QT dispersion indexes, such as QTmax, QTmin, QTd, QTcmax, QTcd and QTcmin in the experimental group were shorter than those in the control group (P<0.05).
conclusionUlinastatin has significant therapeutic efficacy and safety in the clinical treatment of children with severe pneumonia, which may be related to inhibition of the release of inflammatory factors, shortened QT dispersion and the improvement of immune function of peripheral blood T lymphocyte subsets.
Indexed as
Identifiers
37056839PMC10086932W4365478797What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.